Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study

Blood (2025) 146 (Supplement 1): 247.

https://doi.org/10.1182/blood-2025-247

Published: 2025

Journal Articles

Trial in progress: CAR-T (idecabtagene vicleucel) in advanced myeloma plus iberdomide or usual monitoring (The Alliance A062102 CADMIUM Study)

Blood (2025) 146 (Supplement 1): 2289.

https://doi.org/10.1182/blood-2025-2289

Published: 2025

Journal Articles

Restarting etentamig therapy after dosing delays or interruptions: Population pharmacokinetics (PopPK) and PK/PD simulations and supporting clinical data

Sneha Rathi, Vanessa Schmitt, Heiko Babel, Peter Voorhees, Cesar Rodriguez Valdes, Ziyi Jin, Anders Svensson, Chetasi Talati, Benjamin Engelhardt, Akshanth Polepally

Blood (2025) 146 (Supplement 1): 2266.

https://doi.org/10.1182/blood-2025-2266

Published: 2025

Journal Articles

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Blood (2025) 146 (Supplement 1): 372.

https://doi.org/10.1182/blood-2025-372

Published: 2025

Journal Articles

Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses

Blood (2025) 146 (Supplement 1): 2204.

https://doi.org/10.1182/blood-2025-2204

Published: 2025

Journal Articles

Standardizing lines of treatment (LOT) in multiple myeloma: Real-world validation of an automated rule-based algorithm

Blood (2025) 146 (Supplement 1): 8154.

https://doi.org/10.1182/blood-2025-8154

Published: 2025

Journal Articles

Minimal residual disease dynamics in post-transplant patients with newly diagnosed multiple myeloma who received daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in the auriga study

Blood (2025) 146 (Supplement 1): 97.

https://doi.org/10.1182/blood-2025-97

Published: 2025

Journal Articles

Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 94.

https://doi.org/10.1182/blood-2025-94

Published: 2025

Journal Articles

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

Doris Hansen, Lauren Peres, Danai Dima, Saurabh Zanwar, Omar Alexis Castaneda Puglianini, Alicia Richards, Mahmoud Gaballa, Oren Pasvolsky, Aimaz Afrough, Brett Reid, Ariel Grajales-Cruz, Zhuoer Xie, Utkarsh Goel, Aishwarya Sannareddy, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Hitomi Hosoya, Lekha Mikkilineni, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Peter Cheng, Christian Gordillo, Eli Zolotov, Evguenia Bhurtel, Jeries Kort, Raffaella Cassano Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Rahul Banerjee, Leyla Shune, Ran Reshef, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Frederick Locke, Yi Lin, Surbhi Sidana, Krina Patel

Blood (2025) 146 (Supplement 1): 93.

https://doi.org/10.1182/blood-2025-93

Published: 2025

Journal Articles

Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma

Aarif Ahsan, Adam Luo, Cesar Rodriguez Valdes, Peter Voorhees, Anita D'Souza, Alfred Chung, Sascha Tuchman, Hana Safah, John Mckay, Katja Weisel, Raphael Teipel, Neha Korde, Ravi Vij, Shaji Kumar, Thomas Doerr, Rajvineeth Kumar Pothacamury, Chetasi Talati, Brenda Chyla, Jeremy Ross

Blood (2025) 146 (Supplement 1): 5813.

https://doi.org/10.1182/blood-2025-5813

Published: 2025

Journal Articles

Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 6375.

https://doi.org/10.1182/blood-2025-6375

Published: 2025

Journal Articles

Charlotte African American MGUS project (CHAAMP): A prospective pilot study of MGUS screening in black and/or African American adults

Manisha Bhutani, Myra Robinson, Margarita Dzhanumova, Samantha Bradley, Adrienne Dobbins, Robin Cox, David Foureau, Shebli Atrash, Barry Paul, Cindy Varga, Christopher Ferreri, Reed Friend, Mauricio Pineda-Roman, Brittany Neelands, Joseph Mikhael, Nadine Barrett, Peter Voorhees

Blood (2025) 146 (Supplement 1): 8244.

https://doi.org/10.1182/blood-2025-8244

Published: 2025

Journal Articles

T-cell redirecting therapies in multiple myeloma: Barriers and knowledge gap among patients, community physicians, and caregivers

Abena Prempeh, Myra Robinson, Zalak Shah, Ami Ndiaye, Nicole Serapin, Barry Paul, Cindy Varga, Reed Friend, Christopher Ferreri, Shebli Atrash, John Mckay, Peter Voorhees, Manisha Bhutani

Blood (2025) 146 (Supplement 1): 6347.

https://doi.org/10.1182/blood-2025-6347

Published: 2025

Journal Articles

Real-world outcomes of immune effector cell-associated hemophagocytic syndrome (IEC-HS) following ide-cel and cilta-cel therapy in relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 719.

https://doi.org/10.1182/blood-2025-719

Published: 2025

Journal Articles

Optimal ferritin threshold to diagnose immune effector cell-associated hemophagocytic syndrome (IEC-HS) following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 717.

https://doi.org/10.1182/blood-2025-717

Published: 2025

Journal Articles

Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

Blood (2025) 146 (Supplement 1): 4069.

https://doi.org/10.1182/blood-2025-4069

Published: 2025

Journal Articles

Talquetamab for relapsed/refractory multiple myeloma : Real-world outcomes from the US multiple myeloma immunotherapy consortium

Blood (2025) 146 (Supplement 1): 137.

https://doi.org/10.1182/blood-2025-137

Published: 2025

Journal Articles

Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

Ran Reshef, Alexandria Jensen, Christian Gordillo, Brett Reid, Danai Dima, Lauren Peres, Mahmoud Gaballa, Rahul Banerjee, Oren Pasvolsky, Aimaz Afrough, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Vanna Hovanky, Saurabh Zanwar, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Omar Puglianini, Gabriel De Avila, Eli Zolotov, Evguenia Bhurtel, Ariel Grajales-Cruz, Utkarsh Goel, Aishwarya Sannareddy, Jeries Kort, Raffaella Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Zhuoer Xie, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Leyla Shune, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Saurabh Dahiya, Frederick Locke, David Miklos, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Yi Lin, Krina Patel, Doris Hansen, Surbhi Sidana

Blood (2025) 146 (Supplement 1): 134.

https://doi.org/10.1182/blood-2025-134

Published: 2025

Journal Articles

Treatment patterns and real-world effectiveness in patients with Relapsed/Refractory multiple myeloma (RRMM) and lenalidomide-exposure who received 1 to 3 prior lines of therapy

Shiyin Jiao, Jiawen Chen, Rajesh Kamalakar, Kojo Osei-Bonsu, Chetasi Talati, Steve Stricker, Tamas Vizkelety, Kaustav Chatterjee, Peter Voorhees

Blood (2025) 146 (Supplement 1): 4565.

https://doi.org/10.1182/blood-2025-4565

Published: 2025

Journal Articles

Tradeoff between vaccine-induced immunity and depth of response following autologous stem cell transplantation in multiple myeloma

David Foureau, Dragos Plesca, Fei Guo, Barry Paul, Christopher Ferreri, Shebli Atrash, Cindy Varga, Reed Friend, Ami Ndiaye, Lawrence Druhan, Allison Karabinos, Jessica McElwee, Grace Elsey, Allison Morse, Meagan Reinfried, Alexandra Wolff, Peter Voorhees, Manisha Bhutani

Blood (2025) 146 (Supplement 1): 4005.

https://doi.org/10.1182/blood-2025-4005

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study

Trial in progress: CAR-T (idecabtagene vicleucel) in advanced myeloma plus iberdomide or usual monitoring (The Alliance A062102 CADMIUM Study)

Restarting etentamig therapy after dosing delays or interruptions: Population pharmacokinetics (PopPK) and PK/PD simulations and supporting clinical data

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses

Standardizing lines of treatment (LOT) in multiple myeloma: Real-world validation of an automated rule-based algorithm

Minimal residual disease dynamics in post-transplant patients with newly diagnosed multiple myeloma who received daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in the auriga study

Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma

Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)

Charlotte African American MGUS project (CHAAMP): A prospective pilot study of MGUS screening in black and/or African American adults

T-cell redirecting therapies in multiple myeloma: Barriers and knowledge gap among patients, community physicians, and caregivers

Real-world outcomes of immune effector cell-associated hemophagocytic syndrome (IEC-HS) following ide-cel and cilta-cel therapy in relapsed/refractory multiple myeloma

Optimal ferritin threshold to diagnose immune effector cell-associated hemophagocytic syndrome (IEC-HS) following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM)

Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

Talquetamab for relapsed/refractory multiple myeloma : Real-world outcomes from the US multiple myeloma immunotherapy consortium

Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

Treatment patterns and real-world effectiveness in patients with Relapsed/Refractory multiple myeloma (RRMM) and lenalidomide-exposure who received 1 to 3 prior lines of therapy

Tradeoff between vaccine-induced immunity and depth of response following autologous stem cell transplantation in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only